Biomedical and Life Sciences 58 SCSU Academic & Library Science Building Isabel Chenoweth/SCSU Recent years have seen significant investment, expansion and acquisition of companies from Greater New Haven. The region has established a reputation for meticulous and marketable research through companies such as Arvinas, Biohaven Pharmaceuticals, and Sema4 (a spin-out company of the Icahn School of Medicine at the Mount Sinai Genomics research facility in Branford). The Bioscience sector also continues to grow, with Greater New Haven ranked as the second largest bioscience region in New England. A good portion of the Bioscience cluster can be attributed to Medtronic in North Haven, the Icahn School of Medicine of Mt. Sinai in Branford, Yale University School of Medicine, Yale New Haven Hospital and spinoffs from these institutions. Recent Milestones The Frank H. Netter MD School of Medicine at Quinnipiac University recently expanded its research capabilities with a $2 million state-of-the- art lab: The 6,000-square-foot laboratory is a model facility with sophisticated equipment for mammalian cell and microbial culture, analysis of biological materials including DNA, RNA, and proteins, and confocal microscopy of biological tissues. In addition to pursing original research, faculty will use the laboratory to develop and deliver new curriculum experiences. The newly opened Yale Center for Genome Analysis, a collaboration between the Yale School of Medicine and Yale New Haven Hospital, is a full-service facility dedicated to providing RNA expression profiling, DNA genotyping, and high- throughput sequencing using state-of-the-art technologies. The research at the Center represents the next step toward personalized medicine. Thetis Pharmaceuticals was awarded a $2.3 million Fast-Track NIH grant to support development of its TP-317 candidate as oral therapy for treatment of ulcerative colitis. Melinta Therapeutics received approval from the U.S. Food and Drug Administration (FDA) for Baxdela™ (delafloxacin), indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria, including MRSA. Biohaven Pharmaceutical, a clinical-stage biopharmaceutical company that develops drugs to treat migraines, anxiety, depression and rare neurological diseases, raised $168 million in its initial public in May 2017. Arvinas has entered into a $830 million agreement with Pfizer Inc. that covers the discovery and development of potential PROTAC clinical candidates designed to degrade several key disease- causing proteins in multiple therapeutic areas.